Literature DB >> 15046532

ADHD treatment across the life cycle.

Thomas J Spencer1.   

Abstract

Since attention-deficit/hyperactivity disorder (ADHD) is usually diagnosed in children, evidence from the studies of pharmacologic treatments for children with ADHD is used to inform pharmacologic treatment recommendations for adults. A large percentage of children diagnosed with ADHD have symptoms that persist into adolescence and adulthood. Evidence shows that pharmacologic treatments improve functional outcomes in children with ADHD, and studies using similar pharmacologic treatments show positive results in adults with ADHD. This article reviews the use of long-acting methylphenidate, mixed amphetamine salts, desipramine, monoamine oxidase inhibitors, bupropion, and atomoxetine in studies of children, adolescents, and adults with ADHD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15046532

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  12 in total

1.  Drug use related problems among nonmedical users of prescription stimulants: a web-based survey of college students from a Midwestern university.

Authors:  Sean Esteban McCabe; Christian J Teter
Journal:  Drug Alcohol Depend       Date:  2007-07-12       Impact factor: 4.492

2.  Overexpression of the type 1 adenylyl cyclase in the forebrain leads to deficits of behavioral inhibition.

Authors:  Xuanmao Chen; Hong Cao; Amit Saraf; Larry S Zweifel; Daniel R Storm
Journal:  J Neurosci       Date:  2015-01-07       Impact factor: 6.167

Review 3.  Role of zinc in the pathogenesis of attention-deficit hyperactivity disorder: implications for research and treatment.

Authors:  Peter Lepping; Markus Huber
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

Review 4.  The scientific foundation for understanding attention-deficit/hyperactivity disorder as a valid psychiatric disorder.

Authors:  Stephen V Faraone
Journal:  Eur Child Adolesc Psychiatry       Date:  2005-02       Impact factor: 4.785

5.  Neuropharmacological effect of methylphenidate on attention network in children with attention deficit hyperactivity disorder during oddball paradigms as assessed using functional near-infrared spectroscopy.

Authors:  Masako Nagashima; Yukifumi Monden; Ippeita Dan; Haruka Dan; Daisuke Tsuzuki; Tsutomu Mizutani; Yasushi Kyutoku; Yuji Gunji; Mariko Y Momoi; Eiju Watanabe; Takanori Yamagata
Journal:  Neurophotonics       Date:  2014-05-28       Impact factor: 3.593

Review 6.  Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder During Adolescence in the Primary Care Setting: A Concise Review.

Authors:  Khyati Brahmbhatt; Donald M Hilty; Mina Hah; Jaesu Han; Kathy Angkustsiri; Julie B Schweitzer
Journal:  J Adolesc Health       Date:  2016-05-18       Impact factor: 5.012

7.  Objective Measures of Behavior Manifestations in Adult ADHD and Differentiation from Participants with Bipolar II Disorder, Borderline Personality Disorder, Participants with Disconfirmed ADHD as Well as Normative Participants.

Authors:  Hanna Edebol; Lars Helldin; Torsten Norlander
Journal:  Clin Pract Epidemiol Ment Health       Date:  2012-11-02

8.  The effects of long-term medication on growth in children and adolescents with ADHD: an observational study of a large cohort of real-life patients.

Authors:  Shelagh Gwendolyn Powell; Morten Frydenberg; Per Hove Thomsen
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2015-10-28       Impact factor: 3.033

9.  Right prefrontal activation as a neuro-functional biomarker for monitoring acute effects of methylphenidate in ADHD children: An fNIRS study.

Authors:  Yukifumi Monden; Haruka Dan; Masako Nagashima; Ippeita Dan; Daisuke Tsuzuki; Yasushi Kyutoku; Yuji Gunji; Takanori Yamagata; Eiju Watanabe; Mariko Y Momoi
Journal:  Neuroimage Clin       Date:  2012-10-10       Impact factor: 4.881

10.  A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD.

Authors:  Timothy E Wilens; Thorsten Klint; Lenard Adler; Scott West; Keith Wesnes; Ole Graff; Birgit Mikkelsen
Journal:  Behav Brain Funct       Date:  2008-06-13       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.